Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22134638 | 0.82 | ALDH1A1 (0.41) | TRPV1ALDH1A1LMNAMAPTHTT | |
| SCHEMBL25815359 | 0.80 | ALDH1A1 (0.41) | TRPV1ALDH1A1LMNAMAPTHTT | |
| SCHEMBL22134640 | 0.77 | MAPT (0.38) | TRPV1ALDH1A1LMNAMAPTHTT | |
| SCHEMBL22134636 | 0.76 | CYP19A1 (0.44) | TRPV1ALDH1A1LMNAMAPTHTT | |
| SCHEMBL22134634 | 0.75 | CYP19A1 (0.39) | TRPV1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL25815406 | 0.75 | CYP19A1 (0.38) | TRPV1ALDH1A1LMNAMAPTHTT | |
| SCHEMBL25814633 | 0.72 | CYP19A1 (0.36) | TRPV1ALDH1A1LMNAMAPTHTT | |
| SCHEMBL22134728 | 0.71 | FFAR1 (0.39) | ALDH1A1LMNAMAPTHTTSMN1; SMN2 | |
| SCHEMBL25815122 | 0.70 | ALDH1A1 (0.42) | TRPV1ALDH1A1LMNAMAPTHTT | |
| SCHEMBL25815119 | 0.70 | FFAR1 (0.39) | TRPV1ALDH1A1LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219919-A1 | LITHIUM EXTRACTION WITH CROWN ETHERS | ORCA HOLDINGS, LLC | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219919-A1 | LITHIUM EXTRACTION WITH CROWN ETHERS | LCLAT1, LCT, IGF2R | TRPV1 434/4885ALDH1A1 4352/4885LMNA 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.